Reactive species
Human;Mouse;Rat
Applications
WB;IHC;IF;ELISA
Antibody type
Polyclonal Antibody
Immunogen
The antiserum was produced against synthesized peptide derived from the Internal region of human CUL4B. AA range:711-760
Specificity
CUL-4B Polyclonal Antibody detects endogenous levels of CUL-4B protein.
Constitute
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source
Polyclonal, Rabbit,IgG
Dilution rate
WB: 1/500 - 1/2000. IHC-p: 1:100-300 ELISA: 1/20000.. IF 1:50-200
Purification process
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Other name
CUL4B; KIAA0695; Cullin-4B; CUL-4B
Background
This gene is a member of the cullin family. The encoded protein forms a complex that functions as an E3 ubiquitin ligase and catalyzes the polyubiquitination of specific protein substrates in the cell. The protein interacts with a ring finger protein, and is required for the proteolysis of several regulators of DNA replication including chromatin licensing and DNA replication factor 1 and cyclin E. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008],
Function
disease:Defects in CUL4B are the cause of Cabezas X-linked mental retardation syndrome (MRXC) [MIM:300354]; also called X-linked mental retardation with short stature small testes muscle wasting and tremor. MRXC patients show delayed puberty, hypogonadism, relative macrocephaly, moderate short stature, central obesity, unprovoked aggressive outbursts, fine intention tremor, pes cavus, and abnormalities of the toes.,disease:Defects in CUL4B are the cause of X-linked mental retardation-hypotonic facies syndrome type 2 (MRXHF2) [MIM:300639]; also called Smith-Fineman-Myers syndrome type 2 or SFM2. The distinguishing manifestations of MRXHF2 are relative microcephaly, short stature, hypertelorism, macrostomia, patulous lips, difficulty in speech, micrognathia, short thumbs and little fingers with adduction, hypotonia at age less than 10 years, and later hypertonia, restlessness, and seizures
